Marine Clay1, Arnaud Mazouyes2, Melanie Gilson2, Philippe Gaudin3, Athan Baillet3. 1. Grenoble Teaching Hospital, Hopital Sud, Rheumatology department, avenue de Kimberley, 38130 Echirolles cedex, France. Electronic address: mclay@chu-grenoble.fr. 2. Grenoble Teaching Hospital, Hopital Sud, Rheumatology department, avenue de Kimberley, 38130 Echirolles cedex, France. 3. Grenoble Teaching Hospital, Hopital Sud, Rheumatology department, avenue de Kimberley, 38130 Echirolles cedex, France; GREPI, AGIM UJF CNRS FRE 3405, 38706 La Tronche, France.
Abstract
OBJECTIVE: To determine whether continuation of tumor necrosis factor inhibitors (TNFi) before surgery increases the risk of surgical site infection (SSI) in rheumatoid arthritis (RA) patients. METHODS: A systematic review of the literature was conducted from January 2000 to May first 2014, using the databases of PubMed, Cochrane review, Embase, and manual research of abstracts presented in scientific congresses. Most included studies were retrospective. We compared the risk of SSI in the case of discontinuation of TNFi versus continuing TNFi treatment before a surgery. RESULTS: Six studies, with a total of 2743 patients (1360 in the group continuing TNFi agent and 1383 in the group discontinuing TNFi) were included. There was a decreased risk of SSI in patients stopping TNFi (relative risk [RR]=0.62 [95% confidence interval [CI] 0.43-0.89], P=0.99, I2=0%). Concerning overall complications, there was also a decreased risk in patients discontinuing TNFi treatment (RR=0.60 [95% CI 0.42-0.87], P=0.26, I2=25%). CONCLUSION: This meta-analysis showed an increased risk of SSI in patients under TNF inhibitor, and a decreased risk of SSI in case of interruption of treatment during the perioperative time.
OBJECTIVE: To determine whether continuation of tumor necrosis factor inhibitors (TNFi) before surgery increases the risk of surgical site infection (SSI) in rheumatoid arthritis (RA) patients. METHODS: A systematic review of the literature was conducted from January 2000 to May first 2014, using the databases of PubMed, Cochrane review, Embase, and manual research of abstracts presented in scientific congresses. Most included studies were retrospective. We compared the risk of SSI in the case of discontinuation of TNFi versus continuing TNFi treatment before a surgery. RESULTS: Six studies, with a total of 2743 patients (1360 in the group continuing TNFi agent and 1383 in the group discontinuing TNFi) were included. There was a decreased risk of SSI in patients stopping TNFi (relative risk [RR]=0.62 [95% confidence interval [CI] 0.43-0.89], P=0.99, I2=0%). Concerning overall complications, there was also a decreased risk in patients discontinuing TNFi treatment (RR=0.60 [95% CI 0.42-0.87], P=0.26, I2=25%). CONCLUSION: This meta-analysis showed an increased risk of SSI in patients under TNF inhibitor, and a decreased risk of SSI in case of interruption of treatment during the perioperative time.
Authors: Katinka Albrecht; Denis Poddubnyy; Jan Leipe; Philipp Sewerin; Christof Iking-Konert; Roger Scholz; Klaus Krüger Journal: Z Rheumatol Date: 2022-03-02 Impact factor: 1.372
Authors: Katinka Albrecht; Denis Poddubnyy; Jan Leipe; Philipp Sewerin; Christof Iking-Konert; Roger Scholz; Klaus Krüger Journal: Z Rheumatol Date: 2021-12-20 Impact factor: 1.372